SCI时时刷

search
+
Frontline Ph-negative B-cell precursor acute lymphoblastic leukemia treatment and the emerging role of blinatumomab
Frontline Ph-negative B-cell precursor acute lymphoblastic leukemia treatment and the emerging role of blinatumomab
This narrative review seeks to summarize chemotherapeutic regimens commonly used for patients with newly diagnosed Philade...
What have we learned about TP53-mutated acute myeloid leukemia?
What have we learned about TP53-mutated acute myeloid leukemia?
TP53 is a tumor suppressor gene frequently mutated in human cancers and is generally associated with poor outcomes. TP53 m...
Venetoclax combined with three-day multi-frequency decitabine (DEC3-VEN) in elder or intensive chemotherapy ineligible patients with newly diagnosed acute myeloid leukemia
In recent years, Venetoclax (Ven) has gained a prominent position in the treatment of newly diagnosed...
Impact of TP53 mutation on genetic and cellular hierarchy profile in complex karyotype AML/MDS with increased blasts
Impact of TP53 mutation on genetic and cellular hierarchy profile in complex karyotype AML/MDS with increased blasts
Complex karyotype (CK), occurring in 10–15% of adult acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) cases...
Genetically determined telomere length in monoclonal gammopathy of undetermined significance, multiple myeloma risk and outcome
The association between leukocyte telomere length (LTL) and cancer risk has been studied, with confli...
A simplified, two-factor clinical prognostic scoring system for patients with newly diagnosed Hodgkins Lymphoma
A simplified, two-factor clinical prognostic scoring system for patients with newly diagnosed Hodgkins Lymphoma
We sought to compare the performance of the SPS with existing prognostic models. The estimated 5-year OS of patients with ...
Impact of lenalidomide-bortezomib-dexamethasone induction on patients with newly diagnosed multiple myeloma and renal impairment: Results from the Connect® MM Registry
Impact of lenalidomide-bortezomib-dexamethasone induction on patients with newly diagnosed multiple myeloma and renal impairment: Results from the Connect® MM Registry
Limited data exist on the effects of induction treatment in patients with newly diagnosed multiple myeloma (NDMM) and rena...
Is CAR T a drug or a therapeutic pathway? Intention to treat versus per protocol analysis of real world studies of CAR-T cell therapy in relapsed refractory diffuse large B cell lymphoma
Is CAR T a drug or a therapeutic pathway? Intention to treat versus per protocol analysis of real world studies of CAR-T cell therapy in relapsed refractory diffuse large B cell lymphoma
Competing interests GI served as consultant and received honoraria from No...
Proteasome inhibitors related thrombotic microangiopathy: a systematic and comprehensive review
Proteasome inhibitors related thrombotic microangiopathy: a systematic and comprehensive review
Proteasome inhibitors (PIs) are crucial in treating multiple myeloma but carry a risk of thrombotic microangiopathy (TMA),...
Neutrophil-to-lymphocyte ratio as a prognostic indicator of mortality in Polycythemia Vera: insights from a prospective cohort analysis
Neutrophil-to-lymphocyte ratio as a prognostic indicator of mortality in Polycythemia Vera: insights from a prospective cohort analysis
We analyzed the neutrophil-to-lymphocyte ratio (NLR) in 1508 patients with PV and found that those with an NLR Ͱ...
Multi-omics reveal immune microenvironment alterations in multiple myeloma and its precursor stages
Multi-omics reveal immune microenvironment alterations in multiple myeloma and its precursor stages
Tumor immune microenvironmental alterations occur early in multiple myeloma (MM) development. In this study, we aim to sys...
Mosaic chromosomal alterations (mCAs) in individuals with monoclonal B-cell lymphocytosis (MBL)
Mosaic chromosomal alterations (mCAs) in individuals with monoclonal B-cell lymphocytosis (MBL)
MBL is a precursor condition to chronic lymphocytic leukemia (CLL), characterized by monoclonal B-cells in blood. Mosaic c...
The third generation AKR1C3-activated prodrug, ACHM-025, eradicates disease in preclinical models of aggressive T-cell acute lymphoblastic leukemia
The third generation AKR1C3-activated prodrug, ACHM-025, eradicates disease in preclinical models of aggressive T-cell acute lymphoblastic leukemia
T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive hematological malignancy that expresses high levels of the en...
Venous thromboembolism in adolescents and young adults with acute lymphoblastic leukemia treated on a pediatric-inspired regimen
Venous thromboembolism in adolescents and young adults with acute lymphoblastic leukemia treated on a pediatric-inspired regimen
Asparaginase (ASP)-containing regimens for acute lymphoblastic leukemia (ALL) are associated with venous thromboembolism (...
Genomic profiles and outcomes in de novo versus therapy-related core binding factor AML
Genomic profiles and outcomes in de novo versus therapy-related core binding factor AML
Core binding factor acute myeloid leukemia (CBF-AML), characterized by the recurrent translocations o...
Optimal infused CD34+ cell dose in multiple myeloma patients undergoing upfront autologous hematopoietic stem cell transplantation
Optimal infused CD34+ cell dose in multiple myeloma patients undergoing upfront autologous hematopoietic stem cell transplantation
Autologous transplantation remains the standard of care for eligible multiple myeloma (MM) patients, yet optimal CD34+ cel...
Thrombosis in myeloproliferative neoplasms: a viewpoint on its impact on myelofibrosis, mortality, and solid tumors
Thrombosis in myeloproliferative neoplasms: a viewpoint on its impact on myelofibrosis, mortality, and solid tumors
This viewpoint summarizes findings from analyses of large personal patient databases of myeloproliferative neoplasms (MPNs...
Drug development in higher-risk myelodysplastic syndromes
In HR-MDS, treatment goals include disease modification leading to a survival benefit. In the frontline setting, HMAs such...
The DLEU2/miR-15a/miR-16-1 cluster shapes the immune microenvironment of chronic lymphocytic leukemia
The DLEU2/miR-15a/miR-16-1 cluster shapes the immune microenvironment of chronic lymphocytic leukemia
The development and progression of chronic lymphocytic leukemia (CLL) depend on genetic abnormalities and on the immunosup...
Publisher Correction: Patient preferences for intervention in the setting of precursor multiple myeloma
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, whi...
Results from Arm A of Phase 1/2 DREAMM-6 trial: belantamab mafodotin with lenalidomide plus dexamethasone in patients with relapsed/refractory multiple myeloma
Results from Arm A of Phase 1/2 DREAMM-6 trial: belantamab mafodotin with lenalidomide plus dexamethasone in patients with relapsed/refractory multiple myeloma
Belantamab mafodotin is a first-in-class humanized, afucosylated, anti-B-cell maturation antigen (BCM...
Impact of COVID-19 on outcomes with teclistamab in patients with relapsed/refractory multiple myeloma in the phase 1/2 MajesTEC-1 study
Impact of COVID-19 on outcomes with teclistamab in patients with relapsed/refractory multiple myeloma in the phase 1/2 MajesTEC-1 study
Competing interests NWCJvdD has served in a consulting/advisory role for A...
Appraising ascorbic acid as a chemoprevention agent for acute myeloid leukaemia using Mendelian Randomisation
Appraising ascorbic acid as a chemoprevention agent for acute myeloid leukaemia using Mendelian Randomisation
Jani CT, Ahmed A, Singh H, Mouchati C, Al Omari O, Bhatt PS, et al. Burden of AML, 1990–2019: estimates from the global bu...
Evaluation of Ki-67 expression and large cell content as prognostic markers in MZL: a multicenter cohort study
Evaluation of Ki-67 expression and large cell content as prognostic markers in MZL: a multicenter cohort study
Marginal zone lymphoma (MZL) can have varied presentations and pathologic features, including high Ki-67 expression (̴...
Impact of age on treatment utilization for newly diagnosed multiple myeloma: a nationwide retrospective cohort study
Impact of age on treatment utilization for newly diagnosed multiple myeloma: a nationwide retrospective cohort study
Humans rely on heuristics to simplify decision-making [1] and often use chronological age as a key fa...
Immune effector cell-associated enterocolitis following chimeric antigen receptor T-cell therapy in multiple myeloma
Immune effector cell-associated enterocolitis following chimeric antigen receptor T-cell therapy in multiple myeloma
We report 14 cases of immune effector cell (IEC)-associated enterocolitis following chimeric antigen receptor T-cell (CAR-...
Clonal dynamics of aggressive systemic mastocytosis on avapritinib therapy
Clonal dynamics of aggressive systemic mastocytosis on avapritinib therapy
We combined WGS and scRNAseq data obtained at several time points for each pt to assess the effect of avapritinib on clona...
Limited stage high grade B-cell lymphoma with MYC, BCL2 and/or BCL6 rearrangements: BCL2 rearrangements drives the poor outcomes
Limited stage high grade B-cell lymphoma with MYC, BCL2 and/or BCL6 rearrangements: BCL2 rearrangements drives the poor outcomes
Competing interests JKL: Consultancy with ADC Therapeutics, Merck, GenMab,...
Patient preferences for intervention in the setting of precursor multiple myeloma
Multiple myeloma (MM) is always preceded by monoclonal gammopathy of undetermined significance (MGUS)...
Acute lymphoblastic leukemia in patients treated with lenalidomide for multiple myeloma: a safety meta-analysis of randomized controlled trials combined with a retrospective study of the WHO’s pharmacovigilance database
Acute lymphoblastic leukemia in patients treated with lenalidomide for multiple myeloma: a safety meta-analysis of randomized controlled trials combined with a retrospective study of the WHO’s pharmacovigilance database
Jones JR, Cairns DA, Menzies T, Pawlyn C, Davies FE, Sigsworth R, et al. Maintenance lenalidomide in newly diagnosed trans...
阅读更多
format_indent_increase